Transdermal fentanyl matrix patches Matrifen® and Durogesic® DTrans® are bioequivalent

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 75, Issue 2, 2010, Pages 225-231

  Kress, Hans G ^a   Boss, Hildegard ^b   Delvin, Thomas ^d   Lahu, Gezim ^b   Lophaven, Søren ^d   Marx, Michael ^c   Skorjanec, Sophie ^b   Wagner, Thomas ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Nycomed GmbH   (Germany)

^c MEDA Manufacturing GmbH   (Germany)

^d Nycomed Denmark   (Denmark)

Author keywords

Bioequivalence; Durogesic DTrans ; Fentanyl; Healthy subjects; Matrifen ; Opioid; Pain; Pharmacokinetics; Phase I; Safety

Indexed keywords

DTRANS; FENTANYL; MATRIFEN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; GEOMETRY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSDERMAL PATCH; VOMITING;

ADMINISTRATION, CUTANEOUS; ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG DELIVERY SYSTEMS; FENTANYL; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 77952922454     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.02.005     Document Type: Article

References (22)

1. Jeal W., Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997, 53:109-138.
2. Clark A.J., Ahmedzai S.H., Allan L.G., Camacho F., Horbay G.L., Richarz U., Simpson K. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr. Med Res. Opin. 2004, 20:1419-1428.
3. Kress H.G., der Von, Laage D., Hoerauf K.H., Nolte T., Heiskanen T., Petersen R., Lundorff L., Sabatowski R., Krenn H., Rosland J.H., Saedder E.A., Jensen N.H. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. J. Pain Symptom. Manage. 2008, 36:268-279.
4. Milligan K., Lanteri-Minet M., Borchert K., Helmers H., Donald R., Kress H.G., Adriaensen H., Moulin D., Jarvimaki V., Haazen L. Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain. J. Pain 2001, 2:197-204.
5. Ahmedzai S., Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-fentanyl comparative trial group. J. Pain Symptom. Manage. 1997, 13:254-261.
6. Staats P.S., Markowitz J., Schein J. Incidence of constipation associated with long-acting opioid therapy: a comparative study. South. Med. J. 2004, 97:129-134.
7. Tassinari D., Sartori S., Tamburini E., Scarpi E., Raffaeli W., Tombesi P., Maltoni M. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J. Palliative Med. 2008, 11:492-501.
8. Cormie P.J., Nairn M., Welsh J. Control of pain in adults with cancer: summary of SIGN guidelines. BMJ 2008, 337:a2154.
9. Dean M. Opioids in renal failure and dialysis patients. J. Pain Symptom. Manage. 2004, 28:497-504.
10. Kornick C.A., Santiago-Palma J., Moryl N., Payne R., Obbens E.A. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Safety 2003, 26:951-973.
11. FDA. Information for healthcare professionals fentanyl transdermal system (marketed as Duragesic® and generics). US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2007. <> (accessed 17.07.09). http://www.ovha.vermont.gov/for-providers/i2a_fda_gov_cder_drug_infosheets_hcp_fentanyl_2007hcp.pdf.
12. Hair P.I., Keating G.M., McKeage K. Transdermal matrix fentanyl membrane patch (matrifen): in severe cancer-related chronic pain. Drugs 2008, 68:2001-2009.
13. Hoy S.M., Keating G.M. Fentanyl transdermal matrix patch (Durotep MT patch; Durogesic DTrans; Durogesic SMAT): in adults with cancer-related pain. Drugs 2008, 68:1711-1721.
14. Janssen-Cilag Ltd. Durogesic® DTrans Transdermal Patch. Summary of product characteristics, 2008. (accessed 17.07.09). http://www.medicines.ie/document.aspx?documentid=10566.
15. Nycomed. Matrifen® Transdermal patch. Summary of product characteristics, 2008. (accessed 17.07.09). http://www.medicines.ie/medicine/12189/SPC/Matrifen+Transdermal+patch/.
16. Marier J.F., Lor M., Potvin D., Dimarco M., Morelli G., Saedder E.A. Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects. J. Clin. Pharmacol. 2006, 46:642-653.
17. Marier J.F., Lor M., Morin J., Roux L., Di Marco M., Morelli G., Saedder E.A. Comparative bioequivalence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir formulation. Brit. J. Clin. Pharmacol. 2007, 63:121-124.
18. Sathyan G., Guo C., Sivakumar K., Gidwani S., Gupta S. Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications. Curr. Med. Res. Opin. 2005, 21:1961-1968.
19. Lambropoulos J., Spanos G.A., Lazaridis N.V., Ingallinera T.S., Rodriguez V.K. Development and validation of an HPLC assay for fentanyl and related substances in fentanyl citrate injection, USP. J. Pharm. Biomed. Anal. 1999, 20:705-716.
20. FDA. Draft guidance on Lidocaine (Patch/Topical). US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2006. (accessed 17.12.09). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm086293.pdf.
21. FDA. Guidance for industry. Statistical approaches to establishing bioequivalence. US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2001. (accessed 17.07.09). http://www.fda.gov/cder/guidance/index.htm.
22. Williams A.C. Transdermal and Topical Drug Delivery: From Theory to Clinical Practice 2003, Pharmaceutical Press, London, UK.